|
EBRD accepts offer for pharmaceuticals company Pliva
The EBRD has accepted the offer from Barr Pharmaceuticals to purchase its
remaining 5.4 per cent shareholding in the Croatian pharmaceuticals company
Pliva at HRK 820 per share. This follows the decision by the pharmaceuticals
company Actavis to withdraw from the bidding process for Pliva.
The EBRD has been a shareholder in Pliva for 10 years, having purchased 11 per
cent of Pliva's shares at the company's IPO in April 1996. The Bank's
investment in Pliva was its first in a Croatian company. Pliva has since
become one of the leading pharmaceutical companies in the region, with
operations throughout Europe and in the USA.
The EBRD is the largest single investor in Croatia, where it has invested €1.5
billion into 75 projects. The Bank is focusing on providing equity financing
to Croatian private companies, privatisation of state-owned enterprises and
commercial financing of infrastructure, especially municipalities.
|
